Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xalacom · 4 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| Xalacom | DRUG | - |
| Xalatan | DRUG | - |
| Timolol | DRUG | - |
| unfixed Latanoprost and Timolol | DRUG | - |
Inclusion Criteria: * Uni- or bilateral diagnosis of primary open angle glaucoma or ocular hypertension on beta-blocker monotherapy or dual therapy in which at least one medication is a beta-blocker for at least 4 weeks prior to screening Exclusion Criteria: * Closed/ barely open anterior chamber...
Xalacom is used for the treatment of open-angle glaucoma and ocular hypertension. It is an ophthalmic medication developed by Pfizer, Inc. for conditions involving elevated pressure in the eye. The drug is administered as eye drops and is intended to lower intraocular pressure in patients with these conditions.
Xalacom is developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE. Pfizer is a multinational pharmaceutical company that has conducted clinical trials for Xalacom in the treatment of open-angle glaucoma and ocular hypertension.
Xalacom is in Phase 3 clinical development. It has completed multiple Phase 3 trials, including postmarketing safety studies and randomized comparisons of dosing regimens. The drug is investigational and remains in clinical development for the treatment of open-angle glaucoma and ocular hypertension.
Xalacom has been studied in several completed Phase 3 trials, including NCT00150267, a 5-year postmarketing safety study with 976 patients, and NCT00159653, a 12-week randomized comparison of evening dosing with 500 patients. Other trials include NCT00219596 and NCT00277498, both evaluating Xalacom in patients with glaucoma.
Xalacom is a fixed combination product containing latanoprost and timolol. One clinical trial, NCT00219596, compared Xalacom with an unfixed combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension, indicating that Xalacom combines these two active ingredients in a single formulation.
Xalacom works by combining two active ingredients, latanoprost and timolol, to lower intraocular pressure in patients with glaucoma. Latanoprost increases the outflow of aqueous humor, while timolol reduces its production. This dual mechanism helps manage elevated eye pressure in conditions like open-angle glaucoma.